Monopar Therapeutics (NASDAQ:MNPR) CFO Quan Anh Vu Acquires 1,500 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Quan Anh Vu purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The stock was bought at an average price of $69.95 per share, with a total value of $104,925.00. Following the transaction, the chief financial officer owned 1,500 shares of the company’s stock, valued at $104,925. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Monopar Therapeutics Stock Performance

MNPR stock traded down $1.11 during midday trading on Monday, reaching $67.66. 207,529 shares of the company traded hands, compared to its average volume of 71,179. The firm has a market capitalization of $451.95 million, a price-to-earnings ratio of -19.69 and a beta of 1.46. Monopar Therapeutics Inc. has a 52-week low of $21.00 and a 52-week high of $105.00. The business has a 50 day moving average of $79.47 and a 200-day moving average of $60.26.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Research analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MNPR. Wellington Management Group LLP bought a new stake in shares of Monopar Therapeutics during the third quarter valued at approximately $18,904,000. Vanguard Group Inc. grew its stake in Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after purchasing an additional 121,729 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics during the 3rd quarter worth $13,048,000. TCG Crossover Management LLC bought a new stake in Monopar Therapeutics during the 3rd quarter valued at $12,496,000. Finally, ADAR1 Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 28.7% in the 3rd quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock worth $10,617,000 after buying an additional 29,025 shares during the period. 1.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MNPR. Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th. Barclays set a $125.00 price objective on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a research report on Monday, October 13th. Leerink Partners assumed coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price for the company. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Finally, Chardan Capital raised their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Sunday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $106.20.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.